Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 19 December 2006. doi:10.1136/ard.2006.060301
Annals of the Rheumatic Diseases 2007;66:798-802
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism.

EXTENDED REPORT

Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide

Patricia M Stassen1, Jan Willem Cohen Tervaert2, Coen A Stegeman1

1 Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 Department of Clinical Immunology, University Hospital Maastricht, Maastricht, The Netherlands

Correspondence to:
MrsP M Stassen
Department of Nephrology, University Medical Center Groningen, PO box 30001, 9700 RB Groningen, The Netherlands; p.m.stassen{at}int.umcg.nl

Background: Active anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is commonly treated with cyclophosphamide, a drug with serious side effects, and with corticosteroids.

Objective: To determine the efficacy of a possible alternative drug for cyclophosphamide, oral mycophenolate mofetil (MMF) 1000 mg twice daily and oral prednisolone 1 mg/kg once daily as remission induction treatment.

Methods: 32 consecutive patients with 34 episodes of active vasculitis who could not be treated with cyclophosphamide were diagnosed for a median (range) of 6.0 (0.3–22) years and experienced 4 (0–14) relapses prior to the current episode. Treatment response and relapse-free survival were analysed.

Results: Complete remission (CR) was obtained in 25 (78%) patients, partial remission (PR) in 6 (19%), whereas 1 (3%) patient did not respond. 19 patients relapsed, 13 (52%) after CR, 14 (3–58) months after starting the treatment and 6 (100%) after PR, 6 (2–10) months after starting the treatment. The median relapse-free survival was 16 months, comparable with the interval between the previous relapse and the current MMF-treated relapse (17 (3–134) months). Relapse-free survival at 1, 3, and 5 years was 63%, 38% and 27%, respectively. Patients who had been treated successfully with cyclophosphamide before responded better (CR 84%, relapse 50%) than those who had not (CR 50%, relapse 100%). Minor gastrointestinal side effects and infections occurred frequently. MMF was prematurely discontinued due to adverse effects in two patients.

Conclusion: MMF, in combination with prednisolone, can induce remission in patients with relapses of AAV intolerant to cyclophosphamide.

Abbreviations: AAV, ANCA-assocciated vasculitis; BVAS, Birmingham Vasculitis Activity Score; CR, complete remission; PR, partial remission; MMF, mycophenolate mofetil; WG, Wegener’s granulomatosis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Gomez-Puerta, J. A., Hernandez-Rodriguez, J., Lopez-Soto, A., Bosch, X. (2009). Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease. Chest 136: 1101-1111 [Abstract] [Full Text]  
  • Spaetgens, B., van Paassen, P., Tervaert, J. W. C. (2009). Influenza vaccination in ANCA-associated vasculitis. Nephrol Dial Transplant 24: 3258-3258 [Full Text]  
  • Flossmann, O, Baslund, B, Bruchfeld, A, Cohen Tervaert, J W, Hall, C, Heinzel, P, Hellmich, B, Luqmani, R A, Nemoto, K, Tesar, V, Jayne, D R W (2009). Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 68: 1125-1130 [Abstract] [Full Text]  
  • Mukhtyar, C, Guillevin, L, Cid, M C, Dasgupta, B, de Groot, K, Gross, W, Hauser, T, Hellmich, B, Jayne, D, Kallenberg, C G M, Merkel, P A, Raspe, H, Salvarani, C, Scott, D G I, Stegeman, C, Watts, R, Westman, K, Witter, J, Yazici, H, Luqmani, R, for the European Vasculitis Study Group, (2009). EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68: 310-317 [Abstract] [Full Text]  
  • de Winter, B. C. M., van Gelder, T. (2008). Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrol Dial Transplant 23: 3386-3388 [Full Text]  
  • Salama, A. D., Cook, H. T., Pusey, C. D., Pepper, R. J. (2008). A Case of Treated ANCA-Associated Vasculitis with Recurrent Renal Failure. CJASN 3: 637-645 [Full Text]  
  • Bosch, X., Guilabert, A., Espinosa, G., Mirapeix, E. (2007). Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review. JAMA 298: 655-669 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs